Linzess (Linaclotide) Patent Expiration, LOE Window & CMS Spending

Linzess (Linaclotide) by AbbVie: FDA Orange Book core substance LOE 2027-02-28 (last listed 2034-02-16), 1 AB generics, $2.47B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN202811 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2027-02-28
Last Listed Patent or Exclusivity Date2034-02-16
Orange Book Patents (*PED Extensions)14 patents (7 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$2.47B
2024 Medicare Part D Spend$1.98B
2024 Medicaid Spend$483.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.